COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Profitability Analysis including gross margin, operating margin, net margin, return on assets, return on equity, return on invested capital. Compare profitability against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Profitability Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.

Return on Equity (ROE)

4.63%

Decreased from previous period

ROE exceeding 1.5x Medical - Pharmaceuticals median of 2.26%. Joel Greenblatt would check if high returns reflect a sustainable advantage.

Return on Assets (ROA)

1.60%

Decreased from previous period

ROA exceeding 1.5x Medical - Pharmaceuticals median of 0.62%. Mohnish Pabrai would see if this advantage is driven by brand or cost leadership.

Return on Capital Employed (ROCE)

5.96%

Decreased from previous period

ROCE exceeding 1.5x Medical - Pharmaceuticals median of 1.75%. Joel Greenblatt would look for a high return on incremental capital.

Gross Profit Margin

19.09%

Decreased from previous period

Gross margin 50-75% of Medical - Pharmaceuticals median of 28.83%. Guy Spier would question if commodity-like dynamics exist.

Operating Profit Margin

3.60%

Decreased from previous period

Operating margin exceeding 1.5x Medical - Pharmaceuticals median of 1.84%. Joel Greenblatt would study if unique processes or brand lift margins.

Net Profit Margin

2.20%

Decreased from previous period

Net margin exceeding 1.5x Medical - Pharmaceuticals median of 1.13%. Joel Greenblatt would see if this advantage is sustainable across cycles.

Select Chart Metric:

3349.T Profitability Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Return on Equity (ROE)

4.63%

Decreased from previous period

ROE exceeding 1.5x Medical - Pharmaceuticals median of 2.26%. Joel Greenblatt would check if high returns reflect a sustainable advantage.

Return on Assets (ROA)

1.60%

Decreased from previous period

ROA exceeding 1.5x Medical - Pharmaceuticals median of 0.62%. Mohnish Pabrai would see if this advantage is driven by brand or cost leadership.

Return on Capital Employed (ROCE)

5.96%

Decreased from previous period

ROCE exceeding 1.5x Medical - Pharmaceuticals median of 1.75%. Joel Greenblatt would look for a high return on incremental capital.

Gross Profit Margin

19.09%

Decreased from previous period

Gross margin 50-75% of Medical - Pharmaceuticals median of 28.83%. Guy Spier would question if commodity-like dynamics exist.

Operating Profit Margin

3.60%

Decreased from previous period

Operating margin exceeding 1.5x Medical - Pharmaceuticals median of 1.84%. Joel Greenblatt would study if unique processes or brand lift margins.

Net Profit Margin

2.20%

Decreased from previous period

Net margin exceeding 1.5x Medical - Pharmaceuticals median of 1.13%. Joel Greenblatt would see if this advantage is sustainable across cycles.

Select Chart Metric: